Zantel Cat and Dog Tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Praziquantel; Fenbendazole

Available from:

Chanelle Pharmaceuticals Manufacturing Limited

ATC code:

QP52AA51; QP52AC13

INN (International Name):

Praziquantel; Fenbendazole

Dosage:

50/500 mg/tablet

Pharmaceutical form:

Tablet

Prescription type:

CAM: Companion Animal Medicine as defined in relevant national legislation

Therapeutic group:

Cats, Dogs

Therapeutic area:

praziquantel, combinations; fenbendazole

Therapeutic indications:

Endoparasiticide

Authorization status:

Authorised

Authorization date:

2001-05-04

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Zantel Cat and Dog Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
A round buff-coloured tablet with a quarter score.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A broad spectrum anthelmintic for the treatment of mixed infections of
gastrointestinal nematodes and cestodes in dogs and
cats.
Zantel Cat and Dog tablets may also be used as an aid in the control
of_ Giardia_ protozoa in dogs and_ Aelurostrongylus_
_abstrusus_ lungworm infection in cats.
4.3 CONTRAINDICATIONS
Do not use in kittens less than 8 weeks of age.
ACTIVE SUBSTANCES (PER TABLET):
Praziquantel
50.0 mg
Fenbendazole
500.0 mg
Ascarids
_Toxocara cati (adult)_
_Toxascaris leonina (immature, adult)_
Hookworms
_Uncinaria stenocephala (immature, adult)_
_Ancylostoma caninum (immature, adult)_
Whipworms
_Trichuris vulpis (adult)_
Tapeworms
_Echinococcus granulosus_
_Echinococcus multilocularis_
_Dipylidium caninum_
_Taenia spp._
_Mesocestoides spp_
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_7_
_/_
_0_
_7_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_3_
_3_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUC